Fig. 2
From: CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
Expression of CD22 in tissue samples from ESCC patients. A Tonsil cancer specimens incubated with PBS without primary antibody (negative control). B CD22 expression in tonsil carcinoma incubated with primary antibody (positive control). C–E Expression of CD22 in ESCC patients. C Membranous CD22 expression. D Cytoplasmic CD22 expression. E CD22 expression in lymphocytes within the tumor. F–I Different levels of CD22 expression as related to H-score. F Negative CD22 expression, score 0, the tumor cell proportion score is 0%. G Weak-positive CD22 expression, the tumor cell proportion score is 0%, score 1. H Moderate-positive CD22 expression, the tumor cell proportion score is 90%, score 2. I Strong-positive CD22 expression, the tumor cell proportion score is 90%, score 3. Scale bar, 100 μm